Virios Therapeutics (VIRI) to Release Quarterly Earnings on Thursday

Virios Therapeutics (NASDAQ:VIRI – Get Free Report) is scheduled to be releasing its earnings data before the market opens on Thursday, August 10th. Analysts expect Virios Therapeutics to post earnings of ($0.07) per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

Virios Therapeutics (NASDAQ:VIRI – Get Free Report) last posted its quarterly earnings data on Thursday, May 11th. The company reported ($0.08) EPS for the quarter. On average, analysts expect Virios Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Get Virios Therapeutics alerts:

Virios Therapeutics Price Performance

Virios Therapeutics stock opened at $1.69 on Tuesday. The company’s 50 day moving average price is $1.74 and its two-hundred day moving average price is $0.97. Virios Therapeutics has a 52 week low of $0.22 and a 52 week high of $9.11.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. State Street Corp purchased a new stake in shares of Virios Therapeutics during the 2nd quarter valued at $45,000. UBS Group AG raised its position in Virios Therapeutics by 528.3% in the first quarter. UBS Group AG now owns 14,137 shares of the company’s stock worth $63,000 after acquiring an additional 11,887 shares during the period. Envestnet Asset Management Inc. raised its position in Virios Therapeutics by 576.3% in the fourth quarter. Envestnet Asset Management Inc. now owns 109,196 shares of the company’s stock worth $26,000 after acquiring an additional 93,050 shares during the period. Susquehanna International Group LLP boosted its stake in Virios Therapeutics by 343.3% in the first quarter. Susquehanna International Group LLP now owns 161,811 shares of the company’s stock valued at $59,000 after acquiring an additional 125,311 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new position in shares of Virios Therapeutics during the 3rd quarter valued at approximately $67,000. Hedge funds and other institutional investors own 25.05% of the company’s stock.

Virios Therapeutics Company Profile

(Get Free Report)

Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.

Read More

• Five stocks we like better than Virios Therapeutics
• How and Why to Invest in Oil Stocks
• 8 Best Meme Stocks to Buy Now
• P/E Ratio Calculation: How to Assess Stocks
• Is Now The Time To Buy XLF Financial ETF?
• What is a Secondary Public Offering? What Investors Need to Know
• Three Ways To Play The Rise In Oil Prices

Receive News & Ratings for Virios Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virios Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.